Opioid Use Disorder Market , By Drug Type (Buprenorphine, Methadone, Naltrexone, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023

Code : CMI4597

Pages :198

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Opioid Use Disorder Market: Key Developments

On August 30, 2023, Emergent BioSolutions Inc., a company that provides solutions for complex and urgent public health threats, announced that NARCAN Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online, in September 2023. Over-the-counter (OTC) access to NARCAN Nasal Spray offers more people the ability to respond in an opioid emergency, helping to save lives and keep people and communities safe.
On March 29, 2023, Emergent BioSolutions Inc., a company that provides solutions for complex and urgent public health threats, announced that the U.S. Food and Drug Administration (FDA) had approved NARCAN Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decided at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with increasing synthetic opioids.
On March 23, 2023, Harm Reduction Therapeutics, a not-for-profit pharmaceutical company, announced that it has entered into a commercial supply agreement with Catalent, Inc., a leader in developing and delivering better treatments to patients around the world. Under this agreement, Catalent, Inc. will manufacture RiVive (3.0 mg), a naloxone nasal spray for harm reduction therapy for emergency treatment of known or suspected opioid overdose.
In December 2022, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced the settlement agreement with State of New Hampshire, a department of Justice U.S. Under the term of agreement, Teva Pharmaceutical Industries Ltd., provides US$ 33.3 Mn to the state of New Hampshire to address the opioid crisis.
In June 2021, Alkem Laboratories Ltd., a pharmaceutical company, announced that U.S. Food and Drug Administration (U.S. FDA) had approved buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, the generic version of suboxone, used to treat opioid addiction.